Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 3, 2001, Pages 981-985

  Boogaerts, M A ^a   Maertens, J ^a   Van der Geest, R ^a   Bosly, A ^a   Michaux, J L ^a   Van Hoof, A ^a   Cleeren, M ^a   Wostenborghs, R ^a   De Beule, K ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYITRACONAZOLE; ITRACONAZOLE;

ADULT; ARTICLE; BACTERIAL INFECTION; BLOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG METABOLISM; DRUG SAFETY; FEMALE; FEVER; HUMAN; HYPOTENSION; LEUKEMIA; LYMPHATIC LEUKEMIA; MALE; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; PAIN; PNEUMONIA; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; ITRACONAZOLE; MALE; MIDDLE AGED;

EID: 0035115280     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.3.981-985.2001     Document Type: Article

References (15)

1. Enhanced bioavailability of itraconazole solution compared with capsules in healthy volunteers
2. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers
3. Itraconazole (IT) compared with amphotericin B (AMB) as empirical therapy for persistent fever of unknown origin (FUO) in neutropenic patients (PTS)
4. Antifungal prophylaxis with itraconazole in prolonged neutropenia: Correlation with plasma levels
5. Itraconazole solution: Higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis
6. Pharmacokinetics of itraconazole following oral administration to normal volunteers
7. Pharmacokinetics of oral antifungals and their clinical implications
8. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia
9. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections
10. Determination of hydroxypropyl-beta-cyclodextrin in plasma and urine by size-exclusion chromatography with post-column complexation
11. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole
12. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units
13. The effect of the food and dose on the oral systemic availability of itraconazole in healthy subjects
14. Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography